基础胰岛素-话题@MedSci

#基础胰岛素#

29篇内容 | 1699人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2198808, encodeId=6bb02198808d8, content=<a href='/topic/show?id=d20f1090c2' target=_blank style='color:#2F92EE;'>#2型糖尿病#</a> <a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=Front Endocrinol ：2型糖尿病患者使用基础胰岛素的疗效和安全性, objectType=article, longId=821790, objectId=b6f6821e902b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679884929961_4754896.png, objectUrl=/article/show_article.do?id=b6f6821e902b, replyNumber=0, likeNumber=78, createdTime=2024-04-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b6f6821e902b, moduleTitle=Front Endocrinol ：2型糖尿病患者使用基础胰岛素的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6f6821e902b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1623091, encodeId=bc13162309143, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=DVDR：基础胰岛素治疗2型糖尿病患者快速血糖监测对糖化血红蛋白的影响, objectType=article, longId=294874, objectId=5fea2948e41f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fea2948e41f, replyNumber=0, likeNumber=72, createdTime=2022-01-30, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fea2948e41f, moduleTitle=DVDR：基础胰岛素治疗2型糖尿病患者快速血糖监测对糖化血红蛋白的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fea2948e41f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623090, encodeId=179a1623090d2, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=Diabetes Care：停止连续血糖监测对2型糖尿病患者基础胰岛素治疗的影响, objectType=article, longId=292215, objectId=973c29221501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=973c29221501, replyNumber=0, likeNumber=84, createdTime=2021-12-20, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=973c29221501, moduleTitle=Diabetes Care：停止连续血糖监测对2型糖尿病患者基础胰岛素治疗的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=973c29221501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623089, encodeId=d56e1623089db, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=Cardiovasc Diabetol：GLP-1受体激动剂VS基础胰岛素——用于2型糖尿病常规治疗后的心血管结局比较, objectType=article, longId=220590, objectId=46c922059001, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46c922059001, replyNumber=0, likeNumber=87, createdTime=2021-11-20, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46c922059001, moduleTitle=Cardiovasc Diabetol：GLP-1受体激动剂VS基础胰岛素——用于2型糖尿病常规治疗后的心血管结局比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46c922059001)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623088, encodeId=c8961623088be, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=Diabetes Obes Metab：每日三次的基础胰岛素治疗中加入短效艾塞那肽对1型糖尿病患者骨代谢的影响, objectType=article, longId=220047, objectId=feb722004e41, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=feb722004e41, replyNumber=0, likeNumber=53, createdTime=2021-11-11, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=feb722004e41, moduleTitle=Diabetes Obes Metab：每日三次的基础胰岛素治疗中加入短效艾塞那肽对1型糖尿病患者骨代谢的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=feb722004e41)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623087, encodeId=a7f5162308eda, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=DOM：基础胰岛素联合口服药物治疗2型糖尿病患者，将基础胰岛素改为甘精胰岛素300U/mL的疗效和安全性观察, objectType=article, longId=218151, objectId=419321815137, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=419321815137, replyNumber=0, likeNumber=58, createdTime=2021-10-07, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=419321815137, moduleTitle=DOM：基础胰岛素联合口服药物治疗2型糖尿病患者，将基础胰岛素改为甘精胰岛素300U/mL的疗效和安全性观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=419321815137)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623086, encodeId=9c2e16230860b, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=J Am Soc Nephrol：肾移植术后早期基础胰岛素治疗与标准护理在预防糖尿病上的效果对比如何？ , objectType=article, longId=216040, objectId=ac9521604062, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac9521604062, replyNumber=0, likeNumber=70, createdTime=2021-08-21, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac9521604062, moduleTitle=J Am Soc Nephrol：肾移植术后早期基础胰岛素治疗与标准护理在预防糖尿病上的效果对比如何？ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac9521604062)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623085, encodeId=36ad16230859a, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=SoliMix结果公布：基础胰岛素与GLP-1RA的复方制剂与预混胰岛素的头对头比较研究, objectType=article, longId=213502, objectId=ee6b2135028f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee6b2135028f, replyNumber=0, likeNumber=87, createdTime=2021-07-01, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee6b2135028f, moduleTitle=SoliMix结果公布：基础胰岛素与GLP-1RA的复方制剂与预混胰岛素的头对头比较研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee6b2135028f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623084, encodeId=bf1f1623084c3, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=2021ADA热点｜新一代基础胰岛素，『甘精胰岛素U300』多项重磅研究备受关注！, objectType=article, longId=213139, objectId=5dfb213139e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dfb213139e5, replyNumber=0, likeNumber=121, createdTime=2021-06-25, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dfb213139e5, moduleTitle=2021ADA热点｜新一代基础胰岛素，『甘精胰岛素U300』多项重磅研究备受关注！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dfb213139e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623083, encodeId=8d8f162308389, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=JAMA:基础胰岛素治疗的2型糖尿病患者采用CGM后，8个月糖化血红蛋白水平显著降低, objectType=article, longId=212619, objectId=0f83212619e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f83212619e2, replyNumber=0, likeNumber=97, createdTime=2021-06-13, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f83212619e2, moduleTitle=JAMA:基础胰岛素治疗的2型糖尿病患者采用CGM后，8个月糖化血红蛋白水平显著降低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f83212619e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623082, encodeId=f1e8162308241, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=平稳控糖！赛诺菲全新基础胰岛素来优时®重磅在华上市, objectType=article, longId=203417, objectId=748620341ef3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=748620341ef3, replyNumber=0, likeNumber=110, createdTime=2020-11-16, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=748620341ef3, moduleTitle=平稳控糖！赛诺菲全新基础胰岛素来优时®重磅在华上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=748620341ef3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623081, encodeId=426f16230811c, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=创新长效基础胰岛素来优时®在华获批，为糖尿病患者提供更平稳有效的血糖控制, objectType=article, longId=200208, objectId=54ee20020894, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54ee20020894, replyNumber=0, likeNumber=65, createdTime=2020-09-05, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54ee20020894, moduleTitle=创新长效基础胰岛素来优时®在华获批，为糖尿病患者提供更平稳有效的血糖控制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54ee20020894)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623080, encodeId=8aed162308045, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=J Diabetes：利西拉肽作为基础胰岛素治疗2型糖尿病成年人的有效性和安全性, objectType=article, longId=189235, objectId=92f618923503, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92f618923503, replyNumber=0, likeNumber=110, createdTime=2020-03-04, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92f618923503, moduleTitle=J Diabetes：利西拉肽作为基础胰岛素治疗2型糖尿病成年人的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92f618923503)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623079, encodeId=72bc16230e949, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=全新一代基础胰岛素类似物德谷胰岛素被列入国家医保目录, objectType=article, longId=178023, objectId=3f0c1e80236c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f0c1e80236c, replyNumber=0, likeNumber=76, createdTime=2019-08-22, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f0c1e80236c, moduleTitle=全新一代基础胰岛素类似物德谷胰岛素被列入国家医保目录, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f0c1e80236c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623078, encodeId=6e6b16230e86c, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=Diabetes Obes Metab：基础胰岛素治疗的2型糖尿病患者治疗持续性与糖化血红蛋白的关系！, objectType=article, longId=124897, objectId=120e12489ecc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=120e12489ecc, replyNumber=0, likeNumber=68, createdTime=2017-12-29, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=120e12489ecc, moduleTitle=Diabetes Obes Metab：基础胰岛素治疗的2型糖尿病患者治疗持续性与糖化血红蛋白的关系！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=120e12489ecc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623077, encodeId=22d416230e7af, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=Diabet Med：糖尿病患者预混、基础胰岛素方案的临床结局数据：RCT vs真实世界, objectType=article, longId=124801, objectId=66861248016f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66861248016f, replyNumber=0, likeNumber=71, createdTime=2017-12-28, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66861248016f, moduleTitle=Diabet Med：糖尿病患者预混、基础胰岛素方案的临床结局数据：RCT vs真实世界, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66861248016f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623076, encodeId=3c0916230e686, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=超长效基础胰岛素类似物诺和达(R) 在中国获得上市批准, objectType=article, longId=115674, objectId=61d11156e4b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61d11156e4b9, replyNumber=0, likeNumber=77, createdTime=2017-10-12, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61d11156e4b9, moduleTitle=超长效基础胰岛素类似物诺和达(R) 在中国获得上市批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61d11156e4b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623075, encodeId=502016230e57e, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=诺和诺德新一代基础胰岛素Tresiba获CFDA批准, objectType=article, longId=114656, objectId=2ef511465684, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ef511465684, replyNumber=0, likeNumber=72, createdTime=2017-09-30, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ef511465684, moduleTitle=诺和诺德新一代基础胰岛素Tresiba获CFDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ef511465684)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623074, encodeId=8c9616230e425, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=Diabetes Obes Metab：不同基础胰岛素治疗2型糖尿病血糖控制有何不同？, objectType=article, longId=112065, objectId=f41c11206501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f41c11206501, replyNumber=0, likeNumber=63, createdTime=2017-09-07, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f41c11206501, moduleTitle=Diabetes Obes Metab：不同基础胰岛素治疗2型糖尿病血糖控制有何不同？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f41c11206501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623073, encodeId=992416230e3db, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=Diabetes Obes Metab：考虑医疗资源使用和成本降糖应选艾塞那肽还是基础胰岛素？, objectType=article, longId=111950, objectId=8bf9111950c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8bf9111950c2, replyNumber=0, likeNumber=78, createdTime=2017-09-06, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8bf9111950c2, moduleTitle=Diabetes Obes Metab：考虑医疗资源使用和成本降糖应选艾塞那肽还是基础胰岛素？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8bf9111950c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

基础胰岛素

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#2型糖尿病# #基础胰岛素#

Front Endocrinol ：2型糖尿病患者使用基础胰岛素的疗效和安全性

2024-04-16发表于上海

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

DVDR：基础胰岛素治疗2型糖尿病患者快速血糖监测对糖化血红蛋白的影响

2022-01-30

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

Diabetes Care：停止连续血糖监测对2型糖尿病患者基础胰岛素治疗的影响

2021-12-20

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

Cardiovasc Diabetol：GLP-1受体激动剂VS基础胰岛素——用于2型糖尿病常规治疗后的心血管结局比较

2021-11-20

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

Diabetes Obes Metab：每日三次的基础胰岛素治疗中加入短效艾塞那肽对1型糖尿病患者骨代谢的影响

2021-11-11

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

DOM：基础胰岛素联合口服药物治疗2型糖尿病患者，将基础胰岛素改为甘精胰岛素300U/mL的疗效和安全性观察

2021-10-07

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

J Am Soc Nephrol：肾移植术后早期基础胰岛素治疗与标准护理在预防糖尿病上的效果对比如何？

2021-08-21

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

SoliMix结果公布：基础胰岛素与GLP-1RA的复方制剂与预混胰岛素的头对头比较研究

2021-07-01

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

2021ADA热点｜新一代基础胰岛素，『甘精胰岛素U300』多项重磅研究备受关注！

2021-06-25

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

JAMA:基础胰岛素治疗的2型糖尿病患者采用CGM后，8个月糖化血红蛋白水平显著降低

2021-06-13

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

平稳控糖！赛诺菲全新基础胰岛素来优时®重磅在华上市

2020-11-16

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

创新长效基础胰岛素来优时®在华获批，为糖尿病患者提供更平稳有效的血糖控制

2020-09-05

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

J Diabetes：利西拉肽作为基础胰岛素治疗2型糖尿病成年人的有效性和安全性

2020-03-04

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

全新一代基础胰岛素类似物德谷胰岛素被列入国家医保目录

2019-08-22

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

Diabetes Obes Metab：基础胰岛素治疗的2型糖尿病患者治疗持续性与糖化血红蛋白的关系！

2017-12-29

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

Diabet Med：糖尿病患者预混、基础胰岛素方案的临床结局数据：RCT vs真实世界

2017-12-28

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

超长效基础胰岛素类似物诺和达(R) 在中国获得上市批准

2017-10-12

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

诺和诺德新一代基础胰岛素Tresiba获CFDA批准

2017-09-30

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

Diabetes Obes Metab：不同基础胰岛素治疗2型糖尿病血糖控制有何不同？

2017-09-07

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

Diabetes Obes Metab：考虑医疗资源使用和成本降糖应选艾塞那肽还是基础胰岛素？

2017-09-06

科室
- - 订阅+
  - 更多科室
工具
服务